[HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D019888:Nelfinavir / Q000627:therapeutic use / Q000633:toxicity*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D018570:Risk Assessment
D019888:Nelfinavir
HAART und Schwangerschaft. Nelfinavir zeigt Uberlegenheit bei der Hepatotoxizität.